3541 POSTER HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer

Lordick, Florian; Bang, Y.; Kang, Yookija; Reyes, Daniela; Manikhas, Georgy M.; Куликов, Е. П.; Stoß, Oliver; Jordan, Bénédicte; Cutsem, Éric Van

doi:10.1016/s1359-6349(07)71044-3

Cited by 27 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high correlation between HER2/neu expression and the intestinal histologic type of GC was reported by several investigators. Lordick et al reported that HER2/neu positivity differed significantly according to the histological subtype (intestinal 34% vs. diffuse 6%) (20). A similar distribution of HER2/neu in the two histological types was also reported in another study involving Chinese GC patients (25.4 vs. 4.7%, P<0.01) (21).…”

Section: Discussionsupporting

confidence: 53%

Simultaneous detection of expression and gene mutations of HER2/neu in Chinese patients with gastric cancer

Zhang

Jian²,

Yang³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. HER2/neu is one of the few identified oncogenes in tumorigenesis. Attention has been focused on the potential effect of HER2/neu mutations in the tyrosine kinase domain on carcinoma-targeted therapy. However, data concerning HER2/neu mutations in Chinese patients with gastric cancer (GC) are limited. This study aimed to detect the expression and somatic mutations of HER2/neu in Chinese patients with GC. Immunohistochemical staining for HER2/neu was performed on 72 formalin-fixed, paraffin-embedded specimens of GC (40 intestinal and 32 diffuse type). The correlation between the overexpression of HER2/neu and clinicopathological parameters was statistically analyzed. Somatic mutations in the tyrosine kinase domain of HER2/ neu in the 72 patients were detected by direct sequencing. In the GC group, overexpression of HER2/neu was detected in 13 of the 72 GC patients and in 4 of the 72 adjacent tissues in the non-tumorous group (18.1 vs. 5.6%, P<0.05). Furthermore, the intestinal type of GC exhibited a higher rate of HER2/neu overexpression than the diffuse type (29.7 vs. 5.7%, P<0.05). The rate of HER2/neu overexpression in stage III-IV (TNM stage) GC cases was significantly higher than that in stage I-II (28.2 vs. 6.6%, P<0.05). HER2/neu overexpression correlated with a significantly less favorable patient survival (P=0.046). No somatic mutations in the tyrosine kinase domain of HER2/ neu were detected in tumor tissues or the corresponding nontumorous ones in the specimens obtained from the 72 Chinese GC patients. Results suggest that overexpression of HER2/ neu is a frequent molecular event strongly associated with a poor patient prognosis, whereas the incidence of somatic mutations of the HER2/neu kinase domain is more likely a low-frequency event in Chinese GC patients.

show abstract

Section: Discussionsupporting

confidence: 53%

Simultaneous detection of expression and gene mutations of HER2/neu in Chinese patients with gastric cancer

Zhang

Jian²,

Yang³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…This is slightly lower than that reported by Yano et al [21] who found a concordance rate of 58.5% between IHC and FISH in the IHC 2+ tumors. In the ToGA trial, the overall concordance between HER2/neu positivity by IHC and FISH was 87% and differences were largely due to FISH-positive cases that were IHC 0/1+ [22]. However, we were not able to assess the overall concordance of protein expression and gene amplification of HER2/neu in GC, and compare it to others as FISH testing was not done for all cases due to financial limitations.…”

Section: Discussionmentioning

confidence: 95%

HER-2/Neu Status in Gastric Carcinomas in a Series of Egyptian Patients and Its Relation to Ki-67 Expression

El-Gendi¹,

Talaat²,

Abdel-Hadi³

2015

OJPathology

View full text Add to dashboard Cite

Objective: HER-2/neu status in gastric carcinomas (GCs) has not been studied before in the Egyptian population. Materials and Methods: Seventy-three GCs were evaluated for the expression of HER-2/neu and Ki-67 using immunohistochemistry (IHC). Fluorescence in situ Hybridization (FISH) was done for HER2/neu IHC score 2+ cases. Results: Out of the 73 gastric carcinomas, 23 (31.5%) were score 0, 17 (23.3%) were score 1+, 23 (31.5%) were score 2+, and 10 (13.7%) were score 3+. FISH analysis revealed that the HER-2/neu gene was amplified in 11 out of the 23 cases (47.8%) scored 2+ by IHC. Therefore, the overall HER-2/neu positivity rate was 28.8% and it was significantly associated with higher T-stage and lymphovascular invasion (LVI). The Ki-67 expression rate ranged between 10% and 100%, with 84.9% of the cases (n = 62) featuring high Ki-67 scores. High Ki-67 score was significantly associated with male sex, tumor grade, and number of positive nodes. HER-2/neu protein expression correlated significantly with Ki-67 score. Twenty tumors showed combined HER-2/neu positivity and high Ki-67 score and were significantly associated with higher T-stage and occurrence of LVI, implying a more aggressive behavior. Conclusions: The rate of HER-2/neu positive GCs in our series simulates universal rates, thereby mandating routine evaluation of HER-2/neu status in all GCs submitted to our laboratory to benefit from trastuzumab therapy. Further studies on a larger number of GCs are required to prove that the concurrent HER-2/neu positivity and high Ki-67 score are markers of worse prognosis.

show abstract

“…[7][8][9] Differences exist in the interpretation of HER2 amplification and protein overexpression in GGEAC compared to breast carcinoma. Current recommendations for the evaluation of HER2 overexpression include the use of immunohistochemical methods initially on resection or biopsy specimens with cases having equivocal results further analyzed for Her2/neu gene amplification by in situ hybridization.…”

Section: Discussionmentioning

confidence: 99%

“…Gastroesophageal junction carcinomas possess a 1.8 to 2.6 times higher prevalence of HER2 gene amplification (24%-32%) compared to gastric carcinomas (9.5%-18%). [7][8][9] The reported rate of HER2 protein overexpression in GEJ carcinoma ranges from 2% to 45%, 10 and that of gastric carcinomas ranges from 8.2% to 53.4%. 3,11 In addition to tumor site, this variance in reported prevalence of HER2/neu gene amplification and protein overexpression may be due to sample size, population diversity, interobserver variability, specimen processing, tumor sampling, as well as differences in methodology.…”

mentioning

confidence: 99%

HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Histopathology, Diagnostic Testing, and Clinical Implications

Hechtman¹,

Polydorides²

2012

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

N Amplification of the human epidermal growth factor receptor 2/neu (HER2/neu) gene and overexpression of the HER2 protein (HER2) have been shown to occur in gastric and gastroesophageal junction adenocarcinoma in a number of studies. With a dismal survival rate, patients with these cancers stand to benefit from the identification of possible molecular targets such as HER2 for both prognostic and therapeutic purposes. Although these and other carcinomas that overexpress HER2 may have a poorer prognosis and exhibit resistance to conventional chemotherapy, they have also recently been shown to respond to targeted therapy with the anti-HER2 antibody trastuzumab. Here, we briefly review the molecular biology, histopathology, diagnostic techniques, and interpretation, as well as the clinical implications, of HER2 amplification/overexpression in gastric and gastroesophageal adenocarcinoma.

show abstract

3541 POSTER HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer

Cited by 27 publications

References 0 publications

Simultaneous detection of expression and gene mutations of HER2/neu in Chinese patients with gastric cancer

Simultaneous detection of expression and gene mutations of HER2/neu in Chinese patients with gastric cancer

HER-2/Neu Status in Gastric Carcinomas in a Series of Egyptian Patients and Its Relation to Ki-67 Expression

HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Histopathology, Diagnostic Testing, and Clinical Implications

Contact Info

Product

Resources

About